Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer Preclinical Models with Addition of Galectin

  Tumor Immunotherapy Efficacy Increased in Both Breast and Prostate Cancer
            Preclinical Models with Addition of Galectin Inhibitor

-- Galectin Therapeutics and Earle A. Chiles Research Institute -

PR Newswire

NORCROSS, Ga., June 12, 2013

NORCROSS, Ga., June 12, 2013 /PRNewswire-USNewswire/ -- Galectin Therapeutics
(NASDAQ: GALT), the leading developer of therapeutics that target galectin
proteins to treat fibrosis and cancer, today announced that preclinical
studies have shown that combining the galectin inhibitor GR-MD-02 with
monoclonal antibodies that function as immune checkpoint blockade inhibitors
enhance shrinkage of prostate and breast cancer tumors. These data were
generated by the laboratory of Dr. William Redmond of the Robert W. Franz
Cancer Research Center in the Earle A. Chiles Research Institute (EACRI) at
Providence Cancer Center (Portland, OR), an expert in tumor immunology and
part of a comprehensive pre-clinical and clinical program in cancer
immunotherapy. The addition of GR-MD-02, a drug that inhibits galectin
proteins, was found to increase tumor shrinkage and enhance survival in immune
competent mice with prostate and breast cancers when combined with one of the
immune checkpoint blockade inhibitors, anti-CTLA-4 or anti-PD-1.

"Immunotherapy with checkpoint blockade inhibitors, such as anti-CTLA-4
monoclonal antibodies (marketed as YERVOY™ by Bristol-Myers Squibb (BMS)) and
anti-PD-1 monoclonal antibodies (in development at BMS and Merck), is an
extremely exciting area for advancing human cancer immunotherapy," said Dr.
Peter G. Traber, President, Chief Executive Officer and Chief Medical Officer,
Galectin Therapeutics. "However, these agents are currently only effective in
a limited percentage of patients. The ability of GR-MD-02 to increase the
effectiveness of these important drugs is a potentially important approach to
enhance cancer immunotherapy."

"The findings of these experiments show that GR-MD-02 had a robust effect on
augmenting the immune response and tumor efficacy when combined with well
characterized agents for cancer immunotherapy," said Dr. Redmond, Assistant
Member at the EACRI. "The experimental tumor models used are relatively
resistant to therapy to checkpoint blockade inhibitors alone, indicating that
the addition of GR-MD-02 may be a potentially important agent in combination

"We have determined that these pre-clinical results are compelling for
clinical translation and we are planning to seek FDA agreement to open a trial
using YERVOY™ (ipilimumab, anti-CTLA-4 mAb, BMS) in combination with GR-MD-02
in patients with advanced melanoma," said Brendan Curti, MD, Medical
Oncologist and Director of the Providence Biotherapy Program at EACRI. "We are
in the process of designing such a trial with Galectin Therapeutics."

Initial data was reported at the Tumor Immunology Keystone Conference in March
of 2013 which showed that treatment with GR-MD-02 augmented CD8+ T-cell
function in mice (poster available on Galectin web site:
http://bit.ly/19gmjHX) These data show that in response to vaccination with an
antigenic protein, inhibition of extracellular galectin-3 with GR-MD-02
increases the T-cell response to vaccination. Data was then obtained in
several syngeneic tumor models in mice to evaluate the efficacy of anti-CTLA-4
and anti-PD1 monoclonal antibodies alone and in combination with GR-MD-02. As
shown below, the addition of GR-MD-02 resulted in augmented tumor shrinkage in
both prostate and breast cancer models.

(Photo: http://photos.prnewswire.com/prnh/20130612/DC30477)

These data were presented as part of the annual stockholder meeting on May 23,
2013 which can be viewed on the Galectin Therapeutics website

Notes to the reader: Checkpoint Blockade involves molecules on the cell
surface of CD4 and CD8 T cells. These molecules serve as "brakes" to
down-modulate or inhibit an anti-tumor immune response. Checkpoint Blockade
Inhibitors release the "brakes" and thereby increases the immune response.
Syngeneic tumor models in mice use mouse tumors in immunologically normal mice
and therefore allow evaluation of the effect of the immune system on the

YERVOY™ is a registered trademark of Bristol-Myers Squibb Company

About Galectin Therapeutics
Galectin Therapeutics (NASDAQ: GALT) is developing promising
carbohydrate-based therapies for the treatment of fibrotic liver disease and
cancer based on the Company's unique understanding of galectin proteins, key
mediators of biologic function. We are leveraging extensive scientific and
development expertise as well as established relationships with external
sources to achieve cost effective and efficient development. We are pursuing a
clear development pathway to clinical enhancement and commercialization for
our lead compounds in liver fibrosis and cancer. Additional information is
available at www.galectintherapeutics.com.

About Robert W. Franz Cancer Research Center, Earle A. Chiles Research
Institute (EACRI), Providence Cancer Center, Portland Oregon
Providence Cancer Center, a part of Providence Health & Services, offers the
latest in cancer services, including diagnostic, treatment, prevention,
education, support and internationally renowned research. The Earle A. Chiles
Research Institute at Providence Cancer Center is one of 10 research
institutions selected to form the International Immuno-Oncology Network. This
global collaboration will focus on helping the body's own immune system fight
cancer and bring more clinical trials to more patients in our community than
ever before. Visit www.providence.org/cancer.

Forward Looking Statements
This press release contains, in addition to historical information,
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements relate to future events or
future financial performance, and use words such as "may," "estimate,"
"could," "expect" and others. They are based on our current expectations and
are subject to factors and uncertainties which could cause actual results to
differ materially from those described in the statements. These statements
include those regarding the potential benefits of using galectin inhibitors in
combination tumor immunotherapy and the consideration of the initiation of a
related clinical trial. Factors that could cause our actual performance to
differ materially from those discussed in the forward-looking statements
include, among others, that our plans, expectations and goals regarding any
potential benefits of our drugs and any future clinical trials are subject to
factors beyond our control. Future clinical trials may not begin or produce
positive results in a timely fashion, if at all, and could prove time
consuming and costly. Plans regarding development, approval and marketing of
any of our drugs, including GR-MD-02, are subject to change at any time based
on the changing needs of our company as determined by management and
regulatory agencies. To date, we have incurred operating losses since our
inception, and our ability to successfully develop and market drugs may be
impacted by our ability to manage costs and finance our continuing operations
For a discussion of additional factors impacting our business, see our Annual
Report on Form 10-K for the year ended December 31, 2012, and our subsequent
filings with the SEC. You should not place undue reliance on forward-looking
statements. Although subsequent events may cause our views to change, we
disclaim any obligation to update forward-looking statements.

SOURCE Galectin Therapeutics Inc.

Website: www.galectintherapeutics.com